Minimize Uncertainty – Make Informed Decisions – Succeed

Neuroscience

Neuroscience Video Recap—January 7, 2026

January 7, 2026Tysabri,Tyruko,multiple sclerosis,SOD1-related ALS,Alzheimer's Disease,Quanterix Simoa,sanofi,Axsome Therapeutics,Sandoz,IRLAB Therapeutics,BioPharma and Tech News,MSRD,Parkinson's Disease,Biogen,NICE,tolebrutinib,Neuroscience News,amyotrophic lateral sclerosis,OtsukaRelapsing-remitting multiple sclerosis,Natalizumab

This Neuroscience video recap highlights key developments across MS, ALS,…

by LucidQuest

Neuroscience

Neuroscience Today — January 7, 2026

January 7, 2026Tyruko,Thermo Fisher,multiple sclerosis,PPD,Alzheimer's Disease,CorEvitas,sanofi,Quanterix,Sandoz,NurExone,BioPharma and Tech News,Biohaven,Parkinson's Disease,neurodegenerative diseases,Biogen,NICE,Neuroscience News,amyotrophic lateral sclerosis,Relapsing-remitting multiple sclerosisNatalizumab,Tysabri

This Neuroscience update covers clinical readouts, regulatory actions,…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics

January 7, 2026Oncology,clinical trials,precision medicine,Regulatory,AML,biopharma,Lucid Diligence Brief,payer access,M&A,investor diligencetargeted protein degradation

Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE + nimacimab in obesity

January 6, 2026clinical trials,obesity,biopharma,Lucid Diligence Brief,payer access,metabolic disease,drug delivery,CB1 pathway,GLP-1 combinationsENHANZE

Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE +…

by Timos Papagatsias

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration

January 5, 2026Oncology,market access,AI in healthcare,clinical development,biopharma,Lucid Diligence Brief,diligence,partnerships,milestones,HKEXpharma R&D

Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration…

by Timos Papagatsias

Endocrinology

Endocrinology Today—January 5, 2026

January 5, 2026Samsung Bioepis,FNIH Biomarkers Consortium,FDA,Virbac,Celltrion,Afon Technology,BioPharma and Tech News,Immutep,Cushings Syndrome,hip bone mineral density,hypoparathyroidism,large-for-gestational-age,Gestational Diabetes,type two diabetes,Ultragenyx,osteogenesis imperfecta,Innovent Biologics,Obstructive Sleep Apnea,Medtronic,Endocrinology News,AbbottCorcept,Entera Bio

Catch up on the latest endocrinology highlights—from major developments and new…

by LucidQuest

Obesity Weekly News

Obesity Video Recap—January 5, 2026

January 5, 2026Daewoong,Gan & Lee,Envlo,GCG,semaglutide,Enavogliflozin,BioPharma and Tech News,Farxiga,GLP-1,Gubra,Novo Nordisk,LIR Life Sciences,Eli Lilly,Cagrilintide,mazdutide,Lupin,Boehringer Ingelheim,Bofanglutide,Orforglipron,Lilly ExploR&D,Innovent Biologics,Catalyze360,GIP,MEDI&GENE,Obesity News,TRIUMPH-4,Dapagliflozin,WOMAC,CagriSema,transdermal GLP/GIPretatrutide,Wegovy oral

This Obesity video recap highlights major Phase 3 readouts, new regulatory…

by LucidQuest

Obesity Weekly News

Obesity Today—January 5, 2026

January 5, 2026Amylin therapy,Enavogliflozin,semaglutide,Cagrilintide,Biocon,Oral Wegovy,BioPharma and Tech News,Lupin,Novo Nordisk,Bofanglutide,Eli Lilly,Structure Therapeutics,mazdutide,Huons,Liraglutide,FastMed,GLP-1 receptor agonist,MEDI&GENE,Innovent Biologics,Hanmi Pharmaceutical,Obesity News,Dual agonist therapyDaewoong Pharmaceutical,CagriSema

This Obesity roundup highlights major clinical milestones, regulatory filings,…

by LucidQuest

Oncology News

Oncology Video Recap—January 5, 2026

January 5, 2026Pancreatic ductal adenocarcinoma,EGFR-mutated non-small cell lung cancer,prostate cancer,Squamous cell anal carcinoma,BioPharma and Tech News,Rybrevant FASPRO,nivolumab,Rybrevant,Opdivo,Lazcluze,ENHERTU,Lazertinib,trastuzumab deruxtecan,Datroway,pertuzumab,Yervoy,Oncology News,Fruzaqla,Datopotamab Deruxtecan,Fruquintinib,platinum-resistant ovarian cancer,HER2 antibody-drug conjugate,HER2-positive breast cancer,Rucaparib,Triple-negative breast cancer,Rubraca,metastatic colorectal cancer,Zynyzipilimumab,Retifanlimab

This Oncology video recap covering news from the last thre weeks brings…

by LucidQuest

Onco_background

Oncology Today—January 5, 2026

January 5, 2026Incyte,Yuhan,astrazeneca,Theriva,takeda,Alphamab,breast cancer,3DMed,BioPharma and Tech News,Simcere,Colorectal Cancer,HUTCHMED,solid tumors,CSPC,Johnson & Johnson,Halda Therapeutics,Monte Rosa Therapeutics,RIPTAC platform,Daiichi Sankyo,Bristol Myers Squibb,Oncology News,BeOne MedicinesNon-small cell lung cancer,Pancreatic ductal adenocarcinoma

This oncology roundup captures major regulatory approvals, strategic portfolio…

by LucidQuest

Hematology

Hematology Today—January 5, 2026

January 5, 2026Diffuse large B-cell lymphoma,Cytokine release syndrome,janssen,Chronic graft-versus-host disease,roche,Non-relapse mortality,Multiple Myeloma,Incyte,Sickle Cell Disease,Antengene,BioPharma and Tech News,Secura Bio,follicular lymphoma,AB Science,FibroGen,SELLAS Life Sciences,Johnson & Johnson,Ayrmid,cutaneous T-cell lymphoma,Gamida Cell,Acute Myeloid Leukemia,Grifols Egypt,Hematology News,Plasma value chain,Orca Bio,Priority Review,Myelodysplastic syndromesFDA Orphan Drug Designation,grifols

This hematology roundup brings together major regulatory decisions, global…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig

January 4, 2026Oncology,clinical trials,market access,Regulatory,biopharma,SCLC,Lucid Diligence Brief,payer access,diligence,partnerships,China biotech,DLL3T-cell engagers

Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…

by Timos Papagatsias

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.